New hope for hard-to-treat breast cancer brain tumors? trial combines radiation with two powerful drugs.
NCT ID NCT06238921
First seen Oct 31, 2025 · Last updated Apr 25, 2026 · Updated 33 times
Summary
This study tests whether adding a type of radiation (stereotactic radiosurgery) and an immunotherapy drug (zimberelimab) to a standard chemotherapy (sacituzumab govitecan) is safe and works better than the chemotherapy alone for people with triple negative breast cancer that has spread to the brain. About 31 adults with this condition will take part. The goal is to control the disease and delay its progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.